Search

Your search keyword '"Canal G"' showing total 193 results

Search Constraints

Start Over You searched for: Author "Canal G" Remove constraint Author: "Canal G"
193 results on '"Canal G"'

Search Results

1. Real-time control of multiple MHD instabilities on TCV by ECRH/ECCD

2. Observations of Heteroclinic Bifurcations in Resistive MHD Simulations of the Plasma Response to Resonant Magnetic Perturbations

3. Overview of NSTX Upgrade initial results and modelling highlights

4. Nanostructured Europium Oxide thin films deposited by pulsed laser ablation of a metallic target in a He buffer atmosphere

5. Enhanced performance in fusion plasmas through turbulence suppression by megaelectronvolt ions

6. Disruption prediction with artificial intelligence techniques in tokamak plasmas

7. Enhanced performance in fusion plasmas through turbulence suppression by megaelectronvolt ions

8. Disruption prediction with artificial intelligence techniques in tokamak plasmas

9. Nilotinib-induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-Chronic Myeloid Leukemia: Final report of the PhilosoPhi34 study

10. DIII-D research advancing the physics basis for optimizing the tokamak approach to fusion energy

11. Overview of JET results for optimising ITER operation

12. DIII-D research advancing the physics basis for optimizing the tokamak approach to fusion energy

13. DIII-D research advancing the physics basis for optimizing the tokamak approach to fusion energy

15. DIII-D research advancing the physics basis for optimizing the tokamak approach to fusion energy

16. Overview of JET results for optimising ITER operation

17. PH plus STEM CELLS (SCS) IN CHRONIC MYELOID LEUKEMIA (CML): TO ERADICATE OR NOT TO ERADICATE, THIS IS THE QUESTION

18. IDENTIFICAZIONE DI MIRNA E GENI TARGET NELL’ANALISI TRASCRITTOMICA DELLE CELLULE CD34+/LIN- DI PAZIENTI CON LEUCEMIA MIELOIDE CRONICA IN FASE CRONICA DOPO 12 MESI DI TERAPIA CON NILOTINIB

19. Progressive Down Regulation of JAK-STAT, Cell Cycle, and ABC Transporter Genes in CD34+/Lin- Cells of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients at Diagnosis Vs. 12 Months of Nilotinib Treatment Vs. Healthy Subjects

20. Overview of plasma rotation studies on the TCABR tokamak

21. IDENTIFICAZIONE DI MIRNA E GENI TARGET NELL’ANALISI TRASCRITTOMICA DELLE CELLULE CD34+/LIN- DI PAZIENTI CON LEUCEMIA MIELOIDE CRONICA IN FASE CRONICA DOPO 12 MESI DI TERAPIA CON NILOTINIB

22. Overview of plasma rotation studies on the TCABR tokamak

23. Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment

24. Nilotinib induced bone marrow CD34+/lin–Ph+ cells early clearance in newly diagnosed CP-chronic myeloid leukemia

25. Identification of genes differently expressed between bone marrow CD34+/LIN-cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs 12 months of first-line nilotinib treatment

26. Nilotinib Deregulates Cell Cycle Checkpoints, ABC Transporters Genes and JAK-STAT Signaling Pathway of CD34+/Lin- Cells in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients after 12 Months of Treatment

27. Jak-2 and Nfkbia Gene Expression Play a Strategic Role in Chronic Myeloid Leukemia (CML) Molecular Response during Early Nilotinib Treatment: The PhilosoPhi34 Data

29. Identification of genes differently expressed between bone marrow CD34+/LIN-cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs 12 months of first-line nilotinib treatment

30. Melhoramento Genético de Euterpe edulis para produção de frutos

31. IDENTIFICATION OF MIRNA AND TARGET GENES IN THE TRANSCRIPTOME ANALYSIS OF CD34+/LIN- CELLS OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AFTER 12 MONTHS OF NILOTINIB THERAPY

33. Gene Expression Profiling and Cellularity of Bone Marrow CD34+/Lin- Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia at Diagnosis Vs. 12 Months of First-Line Nilotinib Treatment

36. NSTX/NSTX-U theory, modeling and analysis results

37. REL-PROTOCOL PHILOSOPHI34 CONFIRMS THAT NILOTINIB RAPIDLY INDUCES CD34+/LIN-PH+ CELLS DISAPPEARANCE IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA (CML) IN CHRONIC PHASE (CP)

38. Jak-2 and Nfkbia Gene Expression Play a Strategic Role in Chronic Myeloid Leukemia (CML) Molecular Response during Early Nilotinib Treatment: The PhilosoPhi34 Data

39. Real-Time Multi-EC-Actuator MHD Control on TCV

40. Fast seeding of NTMs by sawtooth crashes in TCV and their preemption using ECRH

43. The science program of the TCV tokamak: exploring fusion reactor and power plant concepts

46. REL-Protocol PhilosoPhi34: An Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia Patients, to Study the Disappearance of CD34+/Lin-Ph+ Cells from Bone Marrow during Treatment. Preliminary Data

49. Recent TCV results innovative plasma shaping to improve plasma properties and insight

Catalog

Books, media, physical & digital resources